Rabbit antiserum against purified Electrophorus electricus acetylcholine receptor is studied using an immunoprecipitin assay to measure either antibody titer or concentration of toxin-binding sites in solubilized receptor preparations. This antiserum, unlike control serum, blocks the electrophysiological response of the electroplax to carbamylcholine. Toxin (a-neurotoxin, Naja naja) and several cholinergic ligands produce partial inhibition of the reaction of antiserum with purified acetylcholine receptor. Evidence is presented that some of the toxin-binding sites on receptor, purified by affinity chromatography on toxin-agarose conjugates, are occluded by toxin. In addition, evidence is presented that antireceptor antiserum will cause precipitation of more toxinbinding sites present in an initial extract than in purified receptor preparations.
Over the past few years, considerable effort has been directed towards understanding the molecular biology of the acetylcholine receptor (AChR), a large portion of which has been concerned with its purification (1) (2) (3) (4) (5) (6) (7) (8) . Implicit in these efforts is the assumption that knowledge of the structural properties of purified receptor will provide insight into its function in situ. In order to generate a probe of receptor structure and function which could be used to compare receptor purified and in situ, we stimulated anti-AChR antibody production in rabbits. As we have reported (9) , the injection of rabbits with purified receptor resulted in the formation of antireceptor antibodies and subsequently the appearance of flaccid paralysis leading to death. In this paper, we present properties of one antiserum thus obtained and use this antiserum and antitoxin antiserum to study purified eel acetylcholine receptor.
MATERIALS AND METHODS
Preparation of Neurotoxin. Toxin was purified from the venom of the Indian Cobra N. Naja Naja, as previously described (10) . Purified toxin was iodinated with Na 1251 (New England Nuclear Corp., carrier-free) to specific activities of 30-40 Ci/mmol (11) .
Preparation of Acetylcholine Receptor. Acetylcholine receptor was purified from the electric eel, Electrophorus electricus, by affinity chromatography on columns of toxin-agarose conjugates (6 Preparation of Antisera. Anti-acetylcholine receptor antiserum was prepared as previously described (9) . Antitoxin antiserum was prepared by injecting rabbits with a toxinkeyhole limpet hemocyanin complex. Toxin and hemocyanin were mixed on an equal weight basis and coupled with 2.5% glutaraldehyde (14) . The insoluble complex was washed and emulsified with Freund's complete adjuvant. Each rabbit received 2 mg of the complex subcutaneously, another 2 mg after 2 weeks, and was bled 2 weeks later. Goat anti-rabbit immunoglobulin G antiserum (GAR) was prepared using purified rabbit immunoglobulin G. Goats were injected subcutaneously with 5 mg of antigen emulsified in Freund's complete adjuvant, boosted with the same dose after 2 weeks, and bled 2 weeks later. GAR was fractionated by ammonium sulfate precipitation. Protein precipitating between 0 and 35% saturation was collected, dissolved in phosphate buffered saline and dialyzed overnight against phosphate buffered saline. This preparation was titered on normal rabbit serum and used at the ratio of GAR to normal rabbit serum found to give maximum precipitation of protein.
The Precipitation Assay. Antibody titer and, in some experiments, receptor concentration, was determined by radioimmunoassay. lodinated toxin was allowed to bind to receptor, and the toxin-receptor complex reacted with anti-AChR antiserum. The toxin-receptor-antibody complex was then precipitated with GAR using normal rabbit serum as carrier. The (Fig. 1) . Two separate measurements are made in this assay. The plateau portion of the curve is a measure of the number of toxin-binding sites added to the reaction mixture, whereas the initial slope is a measure of antibody titer. Clearly, the determination of toxin-binding site concentration and serum titer in this manner is only valid to the extent that the toxin binding is specific and the reaction of antibody with receptor is not competitive with toxin binding. The initial slope of the curve must also depend upon the specific activity of the receptor used in the assay since the presence of inactive toxin-binding sites could decrease the amount of toxin binding but have no effect on the ability of the receptor to react with antibody.
In an effort to examine these parameters, we first tested the degree to which we could use precipitation of [i25 I]toxin by An alternative explanation which could partially or completely account for incomplete recovery of toxin-binding sites from the affinity column is that receptor is eluted as a toxinreceptor complex. In this form, it may not be detected by an assay employing [lJII]toxin. The toxin might be present as native toxin, an active fragment of native toxin, or as a toxinagarose complex. These possibilities could be tested using antitoxin antiserum.
In order to detect immunoprecipitation of receptor without relying on added toxin, a radioimmunoassay was developed which was identical to that described in With the availability of a radioimmunoassay which did not depend upon toxin binding for detection of receptor precipitation, it was possible to determine whether antitoxin antiserum was able to precipitate purified receptor. The curve in Fig. 4 shows precipitation of [3H Jacetyl receptor by increasing quantities of antitoxin antiserum. It might be argued that the observed precipitation is a consequence of crossreaction between antitoxin and purified receptor. Two facts make this unlikely: First, at high antitoxin concentrations even limited crossreaction should result in precipitation equal to that produced by anti-AChR. However, the maximal precipitation was only 50% of that observed with anti-AChR antiserum. Second, the addition of benzoquinonium inhibits precipitation by approximately 80%, presumably by competing with toxin for sites on the receptor. The failure to achieve 100% inhibition by benzoquinonium, even after prolonged incubation, may reflect either a very tightly bound fraction of toxin or precipitation by antitoxin of some toxin which was labeled during acetylation of the toxin-receptor complex. This latter reaction would be insensitive to benzoquinonium, as is the precipitation of ['2I toxin by antitoxin antiserum. In summary, acetylcholine receptor purified on toxin-agarose con-0U wI jugates exists in part as a toxin-receptor complex, and this complex may be precipitated by antitoxin antiserum.
As previously mentioned, rabbits injected with eel acetylcholine receptor developed paralysis and died. We examined the possibility that some of the antibody species present in the serum were directed against the active site of the receptor. Duplicate sets of tubes were prepared to titrate [8H]acetyl receptor with anti-AChR antiserum. In one set of tubes we added cold toxin to test its ability to inhibit precipitation of [3H]acetyl receptor. The results in Fig. 5 show that the initial slope, but not the plateau, is altered in the presence of toxin. There remain other explanations for the effect of toxin on the antibody titration curve. A portion of the [3H ]acetate might have reacted with toxin bound to receptor. In this case the presence of cold toxin or receptor ligands would serve to displace [3H]acetyl toxin thus decreasing the tritium precipitated by anti-AChR antiserum. The fact that the maximum amount of labeled material precipitated is independent of the presence of receptor ligands makes this explanation unlikely. It might however be argued that the anti-AChR antiserum is contaminated with antitoxin activity and that this activity contributes to the precipitation of [8H1-acetyl receptor.
Although we do find a slight antitoxin activity in the serum used above, precipitation of [3HJacetyl toxin, whether free or bound to receptor by contaminating antitoxin activity is ruled out because: (1) the antitoxin activity is too low by a factor of 100; (2) sera essentially devoid of antitoxin activity have the same effect; and (3) during competition with cold toxin, the antitoxin activity would be almost exclusively active on cold Fig. 6 show that antiserum but not control serum inhibits the response to carbamylcholine. The inhibition of carbamylcholine-induced depolarization by anti-AChR antiserum is not a general property of sera obtained from immunized rabbits. A similar fraction of antitoxin antiserum had the same effect as control serum.
DISCUSSION
The availability of purified eel acetylcholine receptor made possible the preparation of antireceptor antibodies, and led to the observation that the generation of antireceptor antibodies in rabbits is associated with flaccid paralysis. In this paper, we described a system used to assay the activity of these antisera and have noted some properties of receptor interaction with antibody.
During purification of acetylcholine receptor by affinity chromatography on toxin columns, there is a 40-60% loss of toxin-binding sites. Although incomplete elution of receptor probably accounts for most of the loss, it is important to consider other factors as well. We have shown that anti-AChR antiserum is more efficient in precipitating toxin-binding sites from an initial extract of receptor than from a preparation of (1973) purified receptor. This result might be a consequence of purification of some inactive toxin-binding sites no longer capable of binding toxin or of some loss, during purification, of antigenic determinants on the receptor molecule. In addition, we have found that some of the toxin-binding sites on purified receptor are occupied by toxin or toxin conjugated to a fragment of agarose. It seems likely that affinity chromatography using other ligands will also result in purification of a complex between acetylcholine receptor and the ligand used in the column. Since the ligand may be coupled to a small portion of the support medium, it may not be possible to rely on dialysis to separate receptor from its contaminating ligand. These considerations are particularly pertinent in studies of binding sites using equilibrium dialysis and in studies of receptor function in artificial membranes. Carbohydrate analysis of purified receptor containing a ligand-agarose complex might be misleading.
A portion of the antibody activity directed against purified receptor can be blocked by toxin, decamethonium, carbamylcholine, d-tubocurarine, and benzoquinonium, but not choline. The maximal inhibition observed ranged from 6 to 15%. These values might depend upon the extent to which purified receptor is contaminated with toxin from the affinity column.
If, as in Fig. 4 , we can precipitate 50% of the receptor molecules with antitoxin antiserum it seems that at least 50% of the molecules have at least one site occupied by toxin. If each molecule has only one binding site, then the observed inhibition underestimates by a factor of two the maximum possible inhibition. Clearly, the underestimation becomes small very quickly as the number of binding sites per molecule increases. It is possible to estimate the degree to which the maximal observed inhibition reflects the contribution these antibody species make to the whole serum activity. If we assume that only one antibody molecule must bind to receptor to produce a complex that is precipitated by GAR, we calculate that about 25% of the antibody molecules are incapable of binding receptor in the presence of cholinergic ligands.
Anti-AChR antiserum blocks the electrical response of the monocellular electroplax to carbamylcholine. This constitutes a strong argument that the purified acetylcholine receptor preparation contains physiologically significant receptor molecules. It seems probable that the antibody species responsible for the effect on the electroplax also contribute to the paralysis observed in the injected rabbits. The ability to block acetylcholine receptor mediated depolarization may be a consequence of those antibody species whose binding is inhibited by receptor ligands. On the other hand, there may be present in the serum some antibody species capable of inhibiting receptor control of ion permeability without altering its ability to bind cholinergic ligands.
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